This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

A Time to Test Biotechs' Strength

If it is a bubble, then what investors most keenly want to know is, when is it likely to burst.

"I don't view it as a bubble," Drone said. "Industries go in and out of favor," he added, noting that the phenomenon of large full-service pharmaceutical companies facing holes in their drug pipelines from loss of exclusivity could give the biotechs quite a long run. "If a biotech company is attractive, then yes, there's going to be a significant positive upward push on its share price. The large pharma with an established commercial infrastructure can take that asset, even at the higher price, and commercialize it, so it's not that expensive to them.

Mendelson also said that while he doesn't "think it's unlimited," higher valuations probably won't slow down within the next three to four years.

Perhaps the high IPO rate for biotechs and heightened valuations won't end for a year, or more, but investors should definitely keep their eye on the marketplace.

As Schoenebaum said, "Think about what it means when a platform technology company is oversubscribed and trades up 50% on its first day. These are the kinds of things that happen when you look back historically and say, hey, that was a bubble. ... We are in a very, very, special time that raises some questions about when all this ends, and will it end badly or not?"

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
LPDX $5.24 -0.19%
AMGN $163.58 0.00%
BLUE $178.38 0.00%
EPZM $19.10 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs